injected insulin — Competitive Intelligence Brief

injected insulin (injected insulin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: insulin. Area: Diabetes.

phase 3 insulin insulin receptor Diabetes Small molecule

Target snapshot

injected insulin (injected insulin) — Eli Lilly and Company. Injected insulin works by mimicking the action of the body's natural insulin hormone, helping to lower blood sugar levels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
injected insulin TARGET	injected insulin	Eli Lilly and Company	phase 3	insulin	insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (insulin class)

1. Centre Hospitalier Universitaire Dijon · 1 drug in this class
2. Eli Lilly and Company · 1 drug in this class
3. Green Cross Corporation · 1 drug in this class
4. Novo Nordisk A/S · 1 drug in this class